KPIs & Operating Metrics(New)
Growth Metrics

Astrazeneca (AZN) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $2.6 billion.

  • Astrazeneca's Income from Continuing Operations rose 5780.31% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.4 billion, marking a year-over-year increase of 4269.93%. This contributed to the annual value of $12.4 billion for FY2025, which is 4269.93% up from last year.
  • Latest data reveals that Astrazeneca reported Income from Continuing Operations of $2.6 billion as of Q4 2025, which was up 5780.31% from $3.2 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Income from Continuing Operations registered a high of $3.4 billion during Q1 2025, and its lowest value of -$2.0 billion during Q3 2021.
  • In the last 5 years, Astrazeneca's Income from Continuing Operations had a median value of $1.7 billion in 2023 and averaged $1.5 billion.
  • As far as peak fluctuations go, Astrazeneca's Income from Continuing Operations plummeted by 33458.38% in 2021, and later soared by 74534.41% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Income from Continuing Operations stood at -$636.0 million in 2021, then skyrocketed by 222.33% to $778.0 million in 2022, then increased by 15.3% to $897.0 million in 2023, then surged by 85.73% to $1.7 billion in 2024, then skyrocketed by 57.8% to $2.6 billion in 2025.
  • Its Income from Continuing Operations stands at $2.6 billion for Q4 2025, versus $3.2 billion for Q3 2025 and $3.1 billion for Q2 2025.